| Code | CSB-RA011087MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to lonigutamab, targeting the insulin-like growth factor 1 receptor (IGF1R). IGF1R is a transmembrane tyrosine kinase receptor that plays a critical role in cell growth, proliferation, differentiation, and survival through the IGF signaling pathway. Upon ligand binding, IGF1R undergoes autophosphorylation and activates downstream signaling cascades including the PI3K/AKT and MAPK pathways. Aberrant IGF1R signaling has been implicated in various malignancies, including breast cancer, lung cancer, colorectal cancer, and sarcomas, where it contributes to tumor growth, metastasis, and resistance to conventional therapies.
Lonigutamab is a fully humanized IgG1 monoclonal antibody that binds to IGF1R and blocks ligand-induced receptor activation, leading to receptor downregulation and inhibition of downstream signaling. This biosimilar antibody serves as a valuable research tool for investigating IGF1R-mediated cellular processes, studying receptor biology, evaluating therapeutic targeting strategies, and exploring mechanisms of resistance in oncology research.
There are currently no reviews for this product.